CytoSorbents Receives $1.1 Million in Non-Dilutive Funding from the New Jersey Business Tax Certificate Transfer Program
CytoSorbents Receives $1.1 Million in Non-Dilutive Funding from the New Jersey Business Tax Certificate Transfer Program
04/29/20, 12:47 PM
Location
princetonMoney raised
$1 million
Industry
manufacturing
Round Type
seed
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, today announced that it has received $1,092,698, net of transaction costs, in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority (NJEDA).
Company Info
Location
princeton, new jersey, united states
Additional Info
CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based company involved in the R&D and commercialization of medical devices using its proprietary polymer adsorption technology.
CytoSorbents is a leader in the treatment of life-threatening conditions in the ICU and cardiac surgery using blood purification. Its flagship product, CytoSorb®, is distributed in more than 70 countries and has CE Mark approval in the EU for cytokine, bilirubin and myoglobin removal in numerous critical care applications and the removal of ticagrelor and rivaroxaban during cardiothoracic surgery.